U.S. markets close in 5 hours 28 minutes
  • S&P 500

    4,029.17
    -42.53 (-1.04%)
     
  • Dow 30

    34,169.60
    -260.28 (-0.76%)
     
  • Nasdaq

    11,325.09
    -136.40 (-1.19%)
     
  • Russell 2000

    1,860.64
    -32.20 (-1.70%)
     
  • Crude Oil

    81.18
    +1.20 (+1.50%)
     
  • Gold

    1,786.10
    -23.50 (-1.30%)
     
  • Silver

    22.52
    -0.73 (-3.14%)
     
  • EUR/USD

    1.0527
    -0.0003 (-0.03%)
     
  • 10-Yr Bond

    3.5860
    +0.0800 (+2.28%)
     
  • GBP/USD

    1.2197
    -0.0099 (-0.80%)
     
  • USD/JPY

    136.3880
    +2.1170 (+1.58%)
     
  • BTC-USD

    17,081.28
    +46.12 (+0.27%)
     
  • CMC Crypto 200

    403.78
    -7.43 (-1.81%)
     
  • FTSE 100

    7,580.58
    +24.35 (+0.32%)
     
  • Nikkei 225

    27,820.40
    +42.50 (+0.15%)
     

Rhythm Pharma's Setmelanotide Shows Encouraging Action In Hypothalamic Obesity Study

  • Rhythm Pharmaceuticals Inc (NASDAQ: RYTMannounced interim results from a Phase 2 trial of setmelanotide for severe obesity and hyperphagia.

  • As of the data cutoff date of May 6, 11 patients were evaluable for assessment, including nine patients who completed 16 weeks of treatment and two patients who discontinued early due to treatment-related adverse events.

  • Data highlights from an interim analysis (N=11) include:

    • -17.2% mean percentage change in BMI.

    • -15.8% mean change in body weight from a baseline of 107.1 kg.

    • -15.9 kg mean weight loss from baseline.

  • Data highlights from an interim analysis of completers (n=9) include:

    • -19.5% mean change in BMI.

    • -17.8% mean change in body weight from a baseline of 107.8 kg.

    • -17.8 kg mean weight loss from baseline.

  • Setmelanotide also achieved a meaningful reduction in hunger scores. The mean change in hunger score was -2.7 on a scale of 1-10, with 10 being the most hungry.

  • Setmelanotide was observed to be generally well tolerated.

  • Recently, the FDA approved a supplemental marketing application for Imcivree (setmelanotide) for Bardet-Biedl syndrome.

  • Price Action: RYTM shares are down 0.85% at $4.65 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.